Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewL-3'-F2CCG-I
Discontinued Product
1058 has been discontinued.
View all Glutamate (Metabotropic) Group I Receptors products.
Description: Potent group I/group II agonist
Chemical Name: (2S,1'S,2'S)-2-(2'-Carboxy-3',3'-difluorocyclopropyl)glycine
Biological Activity for L-3'-F2CCG-I
Metabotropic glutamate receptor agonist, exhibits "priming" effect on the monosynaptic reflex.
Licensing Information
Sold with the permission of Nippon Chemiphar Co Ltd.
Technical Data for L-3'-F2CCG-I
| M. Wt | 195.12 |
| Formula | C6H7F2NO4 |
| Storage | Desiccate at +4°C |
| Smiles | [H][C@@]1([C@](O)=O)[C@]([C@]([H])(N)C(O)=O)([H])[C@](F)1F |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for L-3'-F2CCG-I
References for L-3'-F2CCG-I
References are publications that support the biological activity of the product.
Ishida and Shinozaki (1999) Inhibition of uptake and release of a novel mGluR agonist (L-F2CCG-I) by anion transport blockers in the rat spinal cord. Neuropharmacology 38 1531 PMID: 10530815
Saitoh et al (1998) Potentiation by DL-α-aminopimelate of a novel mGluR agonist (L-F2CCG-I) on the monosynaptic excitation in the rat spinal cord. Br.J.Pharmacol. 123 771 PMID: 9517398
Shinozaki et al (1996) Pharmacological activities of fluoride CCG derivatives: discovery of a novel agonist for metabotropic glutamate receptors. Soc.Neurosci.Abstr. 22 412.3
View Related Products by Target
View Related Products by Product Action
Keywords: L-3'-F2CCG-I, L-3'-F2CCG-I supplier, Potent, group, I, II, agonists, mGlur, Group, Receptors, mGlu1, mGlu5, mGluR1, mGluR5, Glutamate, Metabotropic, mGlu2, mGlu3, mGluR2, mGluR3, L-3-F2CCG-I, (Metabotropic), 1058, Tocris Bioscience
Citations for L-3'-F2CCG-I
Citations are publications that use Tocris products.
Currently there are no citations for L-3'-F2CCG-I.
Reviews for L-3'-F2CCG-I
There are currently no reviews for this product. Be the first to review L-3'-F2CCG-I and earn rewards!
Have you used L-3'-F2CCG-I?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.